Download PDF
Semin Liver Dis 2012; 32(02): 177-185
DOI: 10.1055/s-0032-1316474
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Liver Transplantation in HIV Patients

Alyson N. Fox
1   Center for Liver Disease and Transplantation, Weill Cornell Medical Center, New York Presbyterian Hospital, New York
,
Parsia A. Vagefi
2   Division of Transplant Surgery, Massachusetts General Hospital, Boston, Massachusetts
,
Peter G. Stock
3   Division of Transplant Surgery, University of California, San Francisco, San Francisco, California
› Author Affiliations
Further Information

Publication History

Publication Date:
03 July 2012 (online)

    Permissions and Reprints

Abstract

In the last three decades, the management of human immunodeficiency virus (HIV) has improved dramatically. The use of combination antiretroviral therapy (ART) has been successful at preventing death and the myriad infectious, malignant, and immune-mediated complications of HIV. Once considered to be a fatal disease, HIV is now considered by many to be a chronic disease; those affected may now live to experience complications of other coexistent diseases. Liver disease has been increasingly recognized as a leading cause of non-HIV/acquired immunodeficiency syndrome- (AIDS-) related morbidity and mortality in this population.[1] [2] [3] Although liver transplantation offers the opportunity to prolong life, the transplant community has been slow to recognize the chronicity of HIV and potential for transplantation within this population. The experience with liver transplantation in HIV-positive patients is evolving and successful outcomes have been observed when specific criteria are used to select candidates.

Keywords

liver transplantation - HIV - viral hepatitis
 

  • References

  • 1 Bica I, McGovern B, Dhar R , et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32 (3) 492-497
    CrossrefPubMedGoogle Scholar
  • 2 Palella Jr FJ, Baker RK, Moorman AC , et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43 (1) 27-34
    CrossrefPubMedGoogle Scholar
  • 3 Weber R, Sabin CA, Friis-Møller N , et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166 (15) 1632-1641
    CrossrefPubMedGoogle Scholar
  • 4 Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993; 6 (6) 602-610
    PubMedGoogle Scholar
  • 5 Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011; 6 (6) 478-482
    CrossrefPubMedGoogle Scholar
  • 6 Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997; 27 (1) 18-24
    CrossrefPubMedGoogle Scholar
  • 7 Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008; 22 (15) 1979-1991
    CrossrefPubMedGoogle Scholar
  • 8 Benhamou Y, Bochet M, Di Martino V , et al; The Multivirc Group. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30 (4) 1054-1058
    CrossrefPubMedGoogle Scholar
  • 9 García-Samaniego J, Rodríguez M, Berenguer J , et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96 (1) 179-183
    PubMedGoogle Scholar
  • 10 Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11 (11) 1425-1430
    CrossrefPubMedGoogle Scholar
  • 11 Murillas J, Rimola A, Laguno M , et al; ESLD-HIV Working Group Investigators. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009; 15 (9) 1133-1141
    CrossrefPubMedGoogle Scholar
  • 12 Subramanian A, Sulkowski M, Barin B , et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138 (1) 159-164
    CrossrefPubMedGoogle Scholar
  • 13 Kemmer NM, Sherman KE. Liver transplantation trends in the HIV population. Dig Dis Sci 2011; 56 (11) 3393-3398
    CrossrefPubMedGoogle Scholar
  • 14 Stock PG, Fung J. Viable strategies to facilitate liver transplantation for human immunodeficiency virus coinfection. Liver Transpl 2009; 15 (9) 1003-1006
    CrossrefPubMedGoogle Scholar
  • 15 Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42 (5) 744-749
    CrossrefPubMedGoogle Scholar
  • 16 Bouscarat F, Samuel D, Simon F, Debat P, Bismuth H, Saimot AG. An observational study of 11 French liver transplant recipients infected with human immunodeficiency virus type 1. Clin Infect Dis 1994; 19 (5) 854-859
    CrossrefPubMedGoogle Scholar
  • 17 Vagefi PA, Parekh J, Ascher NL, Roberts JP, Freise CE. Outcomes with split liver transplantation in 106 recipients: the University of California, San Francisco, experience from 1993 to 2010. Arch Surg 2011; 146 (9) 1052-1059
    CrossrefPubMedGoogle Scholar
  • 18 Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant 2011; 11 (9) 1773-1784
    CrossrefPubMedGoogle Scholar
  • 19 Boyarsky BJ, Hall EC, Singer AL, Montgomery RA, Gebo KA, Segev DL. Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transplant 2011; 11 (6) 1209-1217
    CrossrefPubMedGoogle Scholar
  • 20 Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010; 362 (24) 2336-2337
    CrossrefPubMedGoogle Scholar
  • 21 Stock PG, Roland ME, Carlson L , et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. Transplantation 2003; 76 (2) 370-375
    CrossrefPubMedGoogle Scholar
  • 22 Roland ME, Barin B, Carlson L , et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8 (2) 355-365
    CrossrefPubMedGoogle Scholar
  • 23 Neff GW, Bonham A, Tzakis AG , et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9 (3) 239-247
    CrossrefPubMedGoogle Scholar
  • 24 Ragni MV, Belle SH, Im K , et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188 (10) 1412-1420
    CrossrefPubMedGoogle Scholar
  • 25 Norris S, Taylor C, Muiesan P , et al. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10 (10) 1271-1278
    CrossrefPubMedGoogle Scholar
  • 26 de Vera ME, Dvorchik I, Tom K , et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6 (12) 2983-2993
    CrossrefPubMedGoogle Scholar
  • 27 Duclos-Vallée JC, Féray C, Sebagh M , et al; THEVIC Study Group. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47 (2) 407-417
    PubMedGoogle Scholar
  • 28 Chung RT, Andersen J, Volberding P , et al; AIDS Clinical Trials Group A5071 Study Team. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351 (5) 451-459
    CrossrefPubMedGoogle Scholar
  • 29 Duclos-Vallée JC, Tateo M, Teicher E , et al. Results of liver transplantation in a large cohort of more than 100 hiv infected patients—a monocentric experience. Abstract presented at: American Associated for the Study of Liver Diseases (AASLD); November 4–8, 2011; San Francisco, CA
    PubMedGoogle Scholar
  • 30 Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10 (8) 968-974
    CrossrefPubMedGoogle Scholar
  • 31 Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12 (5) 801-807
    CrossrefPubMedGoogle Scholar
  • 32 Tateo M, Roque-Afonso AM, Antonini TM , et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23 (9) 1069-1076
    CrossrefPubMedGoogle Scholar
  • 33 Coffin CS, Stock PG, Dove LM , et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10 (5) 1268-1275
    CrossrefPubMedGoogle Scholar
  • 34 Chapuis AG, Paolo Rizzardi G, D'Agostino C , et al. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo. Nat Med 2000; 6 (7) 762-768
    CrossrefPubMedGoogle Scholar
  • 35 Schwarz A, Offermann G, Keller F , et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. Transplantation 1993; 55 (1) 95-103
    CrossrefPubMedGoogle Scholar
  • 36 Stock PG, Barin B, Murphy B , et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363 (21) 2004-2014
    CrossrefPubMedGoogle Scholar
  • 37 Di Benedetto F, Di Sandro S, De Ruvo N , et al. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. Transplantation 2010; 89 (6) 733-738
    CrossrefPubMedGoogle Scholar
  • 38 Tricot L, Teicher E, Peytavin G , et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9 (8) 1946-1952
    CrossrefPubMedGoogle Scholar
  • 39 Frassetto LA, Browne M, Cheng A , et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7 (12) 2816-2820
    CrossrefPubMedGoogle Scholar
  • 40 d'Arminio Monforte A, Cozzi-Lepri A, Castagna A , et al; Icona Foundation Study Group. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009; 49 (4) 612-622
    CrossrefPubMedGoogle Scholar
  • 41 Moreno A, Cervera C, Fortun J, Blanes M, Montejo E, Abradelo M , et al. Epidemiology and outcome of infections in HIV/HCV-coinfected liver transplant recipients: A FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18 (1) 70-81
    CrossrefPubMedGoogle Scholar
  • 42 Berretta M, Garlassi E, Cacopardo B , et al. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011; 16 (9) 1258-1269
    CrossrefPubMedGoogle Scholar
  • 43 Rasmussen LD, Dybdal M, Gerstoft J , et al. HIV and risk of venous thromboembolism: a Danish nationwide population-based cohort study. HIV Med 2011; 12 (4) 202-210
    CrossrefPubMedGoogle Scholar
  • 44 Cherian P, Wesal A, Douiri A, Quaglia A, Heneghan M, O'Grady J , et al. Liver transplantation in human immunodeficiency virus infected patients. procoagulant, but is anti thrombotic prophylaxis required?. Liver Transpl 2012; 18 (1) 82-88
    CrossrefPubMedGoogle Scholar
  • 45 Protocol HIVTR: Solid Organ Transplantation in HIV: Multi-Site Study. 2009. Clinical Trials.gov number NCT00074386
    PubMedGoogle Scholar